Abstracts tagged "Bone"

Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting
Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Sebastian Kraus¹, Matthias Englbrecht¹, Juergen Rech², Roland Kocijan¹, Georg A. Schett¹ and Stephanie Finzel¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…
Abstract Number: 2729 • 2013 ACR/ARHP Annual Meeting
Identification Of Osteoarthritis Patients With Chronic Inflammation Driven Disease Progression
Anne Sofie Siebuhr¹, Kristian Kjaer Petersen², Lars Arendt-Nielsen³, Line Egsgaard², Thomas Navndrup Eskehave⁴, Ole Simonsen⁵, Claus Christiansen^4,6, Hans Christian Hoeck⁴, Morten Asser Karsdal⁷ and Anne C. Bay-Jensen⁸, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, ³Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Center for Sensory-Motor Interaction, Aalborg, Denmark, ⁴Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, ⁵Frederikshavn Hospital, Frederikshavn, Denmark, ⁶Nordic Bioscience, Herlev, Denmark, ⁷Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁸Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: In osteoarthritis (OA) it is evident that a subset of patients experiences chronic tissue inflammation and may benefit from anti-inflammatory treatment. The systemic inflammation…
Abstract Number: 1953 • 2013 ACR/ARHP Annual Meeting
The Progression of Cartilage Damage in Rheumatoid Arthritis: A Three Year Prospective 3T- Magnetic Resonance Imaging Study Examining Predictive Factors
Fiona M. McQueen¹, Alexandra McHaffie², Andrew Clarke², Arier Lee³, Quentin Reeves², Barbara Curteis¹ and Nicola Dalbeth⁴, ¹Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ²Radiology, Auckland District Health Board, Auckland, New Zealand, ³Biostatistics and Epidemiology, University of Auckland, Auckland, New Zealand, ⁴Auckland District Health Board, Auckland, New Zealand
Background/Purpose: Cartilage damage impacts on patient disability in RA. The aims of this MRI study were to investigate cartilage damage over 3 years and determine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].